In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/ L) occurred in 46.3% (i. e. very common) of the patients in the irbesartan group and 26.3% of the patients in the placebo group.
Kroonilise neerupuudulikkuse ja väljendunud proteinuuriaga hüpertensiivsetest diabeedipatsientidest esines hüperkaleemiat (≥ 5, 5 mmol/ l) 46, 3% (st väga sage) irbesartaani - ja 26, 3% platseebogrupis.